APA (7th ed.) Citation

D, K., A, J., B, O., KH, G., NS, B., S, C., . . . GM, W. (2023). Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): A randomised, double-blind, non-inferiority substudy of a phase 4 trial. The Lancet. Infectious diseases, 23(8), 974. https://doi.org/10.1016/S1473-3099(23)00114-7

Chicago Style (17th ed.) Citation

D, Kimathi, et al. "Immunogenicity and Safety of Fractional Doses of 17D-213 Yellow Fever Vaccine in HIV-infected People in Kenya (YEFE): A Randomised, Double-blind, Non-inferiority Substudy of a Phase 4 Trial." The Lancet. Infectious Diseases 23, no. 8 (2023): 974. https://doi.org/10.1016/S1473-3099(23)00114-7.

MLA (9th ed.) Citation

D, Kimathi, et al. "Immunogenicity and Safety of Fractional Doses of 17D-213 Yellow Fever Vaccine in HIV-infected People in Kenya (YEFE): A Randomised, Double-blind, Non-inferiority Substudy of a Phase 4 Trial." The Lancet. Infectious Diseases, vol. 23, no. 8, 2023, p. 974, https://doi.org/10.1016/S1473-3099(23)00114-7.